Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of $0.92, $0.05 worse than the analyst estimate of $0.97. Revenue for the quarter came in at $186.5 million versus the consensus estimate of $192.69 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.